Toremifene For Bone Fractures

Last week, GTx Inc. announced the FDA plans to make a ruling on the company's bone drug toremifene by Oct. 30. The drug is intended to prevent bone fractures in men who are undergoing androgen deprivation therapy (ADT) for prostate cancer. GTx has asked the FDA to approve marketing for 80 mg doses of toremifene. Approximately 100,000 men undergo ADT each year and this treatment has a tendency to weaken bones, leading to five to eight percent of men treated with ADT to suffer a bone fracture.

Have a good Thursday.
Blessings,
Rick